Ex-Amplimmune execs reunite for NextCure

Immuno-oncology newco NextCure Inc. (New Haven, Conn.) raised $67 million in a series A round. The company's management team includes former executives from Amplimmune Inc., which AstraZeneca plc (LSE:AZN; NYSE:AZN) acquired in 2013 (see BioCentury, Sept. 9, 2013).

Investors included Canaan Partners, Lilly Asia Ventures, OrbiMed Advisors, Pfizer Inc. (NYSE:PFE), Sofinnova Ventures and Alexandria Venture Investments. ...